The Association believes that the measure lacks a public health justification and runs counter to the differentiated treatment that European regulations grant to these medications. These treatments are already subject to one of the most rigorous evaluation and funding systems within the National Health System.

Economic measures that reduce the attractiveness of the Spanish market may affect the availability of new treatment options for patients

Read the full press releasehere.